Evidence map›Paper›PMID 31355241›Full record

ArticleAnnals of translational medicine2019

A case of chemorefractory metastatic type AB thymoma sensitive to helical tomotherapy.

Zelai He, Huijun Zhang, Zhen Cui, Qijun Jing, Zhe Zhang, Yong Shen, Jingjing Liu, Jingwen Huang

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Zelai HeDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University & Tumor Hospital Affiliated to Bengbu Medical University, Bengbu 233004, China.
Huijun ZhangDepartment of Cardiothoracic Surgery, Huashan Hospital, Fudan University, Shanghai 200333, China.
Zhen CuiDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University & Tumor Hospital Affiliated to Bengbu Medical University, Bengbu 233004, China.
Qijun JingDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University & Tumor Hospital Affiliated to Bengbu Medical University, Bengbu 233004, China.
Zhe ZhangDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University & Tumor Hospital Affiliated to Bengbu Medical University, Bengbu 233004, China.
Yong ShenThe First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
Jingjing LiuDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University & Tumor Hospital Affiliated to Bengbu Medical University, Bengbu 233004, China.
Jingwen HuangAnhui Province Key Laboratory of Translational Cancer Research Affiliated to Bengbu Medical University, Bengbu 233030, China.
Bengbu Medical College · CNFirst Affiliated Hospital of Bengbu Medical College · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type AB thymoma associated with multiple metastases is rarely encountered. This paper describes the therapeutic effect of new radiotherapy, helical tomotherapy (TOMO), in a thymoma patient with multiple metastases. A male patient aged 52 was diagnosed as type AB thymoma with multiple metastases. Two-cycle chemotherapy was administered as the primary therapy. The efficacy evaluation indicated progressive disease (PD), so radiotherapy was added to the initial treatment. The re-evaluation of efficacy indicated PD under chemotherapy and partial response (PR) in the radiotherapy area, so the latter treatment was changed to TOMO. The TOMO treatment was effective. However, due to the severe bone marrow suppression, the radiotherapy was stopped, and the patient was discharged. We concluded that the development of type AB thymoma associated with multiple metastases was fast, and the patient was sensitive to radiotherapy but not chemotherapy. Thus, TOMO can be selected as the primary palliative therapeutic regimen for chemotherapy-resistant thymoma patients, but the patient tolerance of TOMO requires careful evaluation and further clinical study.

Indexed as

chemotherapymetastasisradiotherapyThymomatomotherapy (TOMO)

Identifiers

PMID31355241
PMCPMC6614316
OpenAlexW2947409390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.